Journal Detail Information

1

Cite

Share

Interim Guidelines on Antiviral Therapy for COVID-19

Sun Bean KIM ; Kyungmin HUH ; Jung Yeon HEO ; Eun-Jeong JOO ; Youn Jeong KIM ; Won Suk CHOI ; Yae-Jean KIM ; Yu Bin SEO ; Young Kyung YOON ; Nam Su KU ; Su Jin JEONG ; Sung-Han KIM ; Kyong Ran PECK ; Joon Sup YEOM

Infection and Chemotherapy.2020;52(2):281-304. doi:10.3947/ic.2020.52.2.281

Since the first case was reported in Wuhan, Hubei Province, China on December 12, 2019, Coronavirus disease 2019 (COVID-19) has spread widely to other countries since January 2020. As of April 16, 2020, 10635 confirmed cases have been reported, with 230 deaths in Korea. COVID-19 patients may be asymptomatic or show various clinical manifestations, including acute symptoms such as fever, fatigue, sore throat; pneumonia presenting as acute respiratory distress syndrome; and multiple organ failure. As COVID-19 has such varied clinical manifestations and case fatality rates, no standard antiviral therapy regimen has been established other than supportive therapy. In the present guideline, we aim to introduce potentially helpful antiviral and other drug therapies based on in vivo and in vitro research and clinical experiences from many countries.

2

Cite

Share

The Practice Guideline for Vaccinating Korean Patients with Autoimmune Inflammatory Rheumatic Disease

Yu Bin SEO ; Su-Jin MOON ; Chan Hong JEON ; Joon Young SONG ; Yoon-Kyoung SUNG ; Su Jin JEONG ; Ki Tae KWON ; Eu Suk KIM ; Jae-Hoon KIM ; Hyoun-Ah KIM ; Dong-Jin PARK ; Sung-Hoon PARK ; Jin Kyun PARK ; Joong Kyong AHN ; Ji Seon OH ; Jae Won YUN ; Joo-Hyun LEE ; Hee Young LEE ; Min Joo CHOI ; Won Suk CHOI ; Young Hwa CHOI ; Jung-Hyun CHOI ; Jung Yeon HEO ; Hee Jin CHEONG ; Shin-Seok LEE

Infection and Chemotherapy.2020;52(2):252-280. doi:10.3947/ic.2020.52.2.252

To develop a clinical practice guideline for vaccination in patients with autoimmune inflammatory rheumatic disease (AIIRD), the Korean College of Rheumatology and theKorean Society of Infectious Diseases developed a clinical practice guideline according to the clinical practice guideline development manual. Since vaccination is unlikely to cause AIIRD or worsen disease activities, required vaccinations are recommended. Once patients are diagnosed with AIIRD, treatment strategies should be established and, at the same time, monitor their vaccination history. It is recommended to administer vaccines when the disease enters the stabilized stage. Administering live attenuated vaccines in patients with AIIRD who are taking immunosuppressants should be avoided. Vaccination should be considered in patients with AIIRD, prior to initiating immunosuppressants. It is recommended to administer influenza, Streptococcus pneumoniae, hepatitis A, hepatitis B, herpes zoster, measlesmumps- rubella virus, human papillomavirus, and tetanus-diphtheria-pertussis vaccines in patients with AIIRD; such patients who planned to travel are generally recommended to be vaccinated at the recommended vaccine level of healthy adults. Those who live in a household with patients with AIIRD and their caregivers should also be vaccinated at levels that are generally recommended for healthy adults.

3

Cite

Share

Historical and Clinical Perspective of Vibrio vulnificus Infections in Korea

Seung-Ji KANG ; Sook-In JUNG ; Kyong Ran PECK

Infection and Chemotherapy.2020;52(2):245-251. doi:10.3947/ic.2020.52.2.245

Vibrio vulnificus infection was first reported as a necrotizing skin disease of unknown cause in Korea in 1979. In the early days, this disease caused panic across the country due to dreadful wound and its high mortality. Since then, the nature of the disease has become better understood and the overwhelming public fear has dissipated. However, there are still a certain number of infected patients each year and the high mortality rate remains a major health and social problem. From this review on historical and clinical perspective, better understanding of V. vulnificus infection would provide valuable information for public health planning.

4

Cite

Share

History of Acquired Immune Deficiency Syndrome in Korea

June Myung KIM ; Nam Joong KIM ; Jun Yong CHOI ; Bum Sik CHIN

Infection and Chemotherapy.2020;52(2):234-244. doi:10.3947/ic.2020.52.2.234

The first human immunodeficiency virus (HIV) infection was reported in Korea in 1985. The number of HIV-infected persons domestically increased in the 1990s showing epidemic indigenousization. Since then, the number of new infections gradually increased every year, and recently more than 1,000 newly infected cases were reported per year. A total of 12,522 infected individuals have been reported up to 2015, of which 2,020 died. The male to female ratio was 15.4:1, and 34.2% of them were under 30 years old. The infection route was homosexual and bisexual contact in 60.1% of cases and heterosexual contact in 34.6% of cases. Candidiasis, Pneumocystis pneumonia, tuberculosis were common as a AIDS (acquired immune deficiency syndrome)-defining illness. But with the introduction of antiretroviral therapy in the late 1990s, non-AIDS defining illnesses such as metabolic complications, cardiovascular diseases, bone diseases, and neuropsychiatric disorders such as neurocognitive dysfunction, depression, and anxiety are emerging as new health problems. The management policy switched its focus from regulating and monitoring of HIV-infected persons to ensuring access to treatment and promotion of voluntary HIV testing in high-risk groups. Also as the age of the infected persons increases, a need for various supports such as social rehabilitation, life counseling, and welfare has emerged.

5

Cite